Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 2/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7199648 | 0.85 | HTR2C (0.44) | EPHX2ADAM17MMP13MMP2 | |
| SCHEMBL7202583 | 0.84 | ADAM17 (0.40) | MMP1ADAM17MMP13MMP2 | |
| SCHEMBL7205954 | 0.84 | MMP13 (0.46) | EPHX2MMP1MMP13MMP2 | |
| SCHEMBL7201643 | 0.83 | MMP13 (0.41) | EPHX2MMP1ADAM17HRH3MMP13 | |
| SCHEMBL7205554 | 0.83 | ADAM17 (0.37) | ADAM17ADAM10MMP2 | |
| SCHEMBL7208848 | 0.82 | CHRNB2 (0.44) | EPHX2MMP1ADAM17HRH3MMP13 | |
| SCHEMBL7203079 | 0.82 | HTR2C (0.47) | MMP13ADAM10MMP2 | |
| SCHEMBL7201026 | 0.82 | HTR2C (0.48) | EPHX2UTS2R | |
| SCHEMBL7201577 | 0.82 | MMP1 (0.42) | EPHX2MMP1ADAM17HRH3MMP13 | |
| SCHEMBL7202570 | 0.82 | EPHX2 (0.41) | EPHX2ADAM17MMP13ADAM10MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | EPHX2 368/4885MMP1 8/4885ADAM17 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.